The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study

By sjmartinez • November 26, 2022

Benjamin DJ, Chen S, Eldredge JB, Schokrpur S, Li D, Quan Z, Chan JW, Cummings AL, Daly ME, Goldman JW, Gubens MA, Harris JP, Onaitis MW, Zhu VW, Patel SP, Kelly K. The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study. JTO Clin Res Rep. 2022 Oct 29;3(12):100427. doi: 10.1016/j.jtocrr.2022.100427. PMID: 36426286; PMCID: PMC9679033.

Tags: Actionable mutations, chemotherapy, Driver mutations, General Internal Medicine, immune checkpoint inhibitors, Non–small cell lung cancer, Oncogenic driven, Publications

William J. Carroll, MD, FACP Appointed Section Chief of Palliative Care and Extensivist Medicine

The UCLA Department of Medicine (DoM) is pleased to announce the appointment of William J. Carroll, MD, FACPas section chief of the UCLA DoM Palliative Care[...]

Joshua N. Khalili, MD Appointed to DoM Chief Wellness Officer

The UCLA Department of Medicine has appointed Joshua N. Khalili, MD to chief wellness officer (CWO) effective April 1. The appointment builds on Dr. Khalili’s outstanding work[...]

Sun M. Yoo, MD, MPH to Depart DoM to Pursue New Leadership Opportunity

The UCLA Department of Medicine (DoM) announces that Sun M. Yoo, MD, MPH, will be departing UCLA Health to assume the role of a founding chief[...]